Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4191 - The immune landscape of melanoma significantly influences survival in patients with highly mutated tumors.

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Tumour Site

Melanoma

Presenters

Robert Ferguson

Citation

Annals of Oncology (2019) 30 (suppl_5): v533-v563. 10.1093/annonc/mdz255

Authors

R. Ferguson1, L. Morales1, D. Simpson1, J. Cadley1, E. Esteva1, V. Chat1, C. Martinez1, J.S. Weber2, I. Osman3, T. Kirchhoff1

Author affiliations

  • 1 Perlmutter Cancer Center, New York Langone Health, 10016 - New York/US
  • 2 Xxx, NYU Langone Medical Center, 10016 - New York/US
  • 3 Dermatology, New York Langone Health, 10016 - New York/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4191

Background

Tumor-specific indicators, such as tumor mutation burden (TMB) have been shown to affect overall survival (OS) in melanoma. Recently, pan-cancer analyses from The Cancer Genome Atlas (TCGA) discovered specific tumor immune signatures predictive of overall survival (OS), yet it is unclear how these interact with other prognostic markers, independently of immunotherapy (IT). We aimed to combine the immune landscape signatures with TMB and other prognostic markers to improve melanoma OS prediction in patients, independent of IT.

Methods

We examined the whole-exome data in conjunction with the molecular, clinical and immune features from 278 metastatic melanomas from TCGA, not treated by IT, to develop an improved prognostic model of melanoma OS. Using the discovery (N = 139) and validation (N = 139) design we performed multivariate Cox proportional hazards (Cox HR) models, adjusted for age and tumor stage at primary diagnosis, to identify interaction between TMB and melanoma immune features (n = 59), refining the prediction of melanoma OS.

Results

We identified 4 immune features that were significantly associated with OS in both the discovery and validation cohorts. The multivariate Cox HR models revealed that IFN-γ response (IFN-γ R) and macrophage regulation (MR) signatures in combination with TMB were the most significantly associated with OS (p = 8.80E-14). After further refinement, we observed that patients with high TMB, high IFN-γ R and high MR had significantly better OS compared to high TMB, low IFN-y R and low MR (HR = 2.8, p = 3.55E-08). This association was not observed in low TMB patients.

Conclusions

We show, for the first time, that TMB and tumor immune features are significantly associated with improved OS, independent of IT. Further analysis of patients revealed that high TMB associates with improved OS in patients with high IFN- γ R and MR but not in low IFN- γ R and MR. Hence, this data provides first evidence that patients with high TMB have distinct OS outcome depending on other tumor immune features. Beside biological link between TMB and IFN-y and MR, our data suggest that these associations may significantly improve the current melanoma prognostic models.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

J.S. Weber: Advisory / Consultancy: Merck; Advisory / Consultancy: BMS; Advisory / Consultancy: Novartis; Licensing / Royalties, Biomarker Patient: Biodesix. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.